A Chat with Anat
ApotheCom
"A Chat with Anat" is a series for ophthalmologists who are interested in improving delivery of care for patients living with retinal disease, and for those interested in clinically-challenging situations or controversies in care. I’m Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss these important topics. This podcast series is sponsored and organized by Bayer and produced by ApotheCom.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences.
All episodes
Best episodes
Seasons
Top 10 A Chat with Anat Episodes
Goodpods has curated a list of the 10 best A Chat with Anat episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to A Chat with Anat for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite A Chat with Anat episode by adding your comments to the episode page.
03/01/22 • 19 min
My guest is Dr. Jane Barratt, Secretary General of the International Federation on Ageing. In this episode, Jane and I discuss ways in which we can improve our communication with our patients to enable realistic expectation-setting. We also speak about how we can meaningfully engage with, and empower, our patients to support them in managing their nAMD.
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
World Sight Day and collaboration for change in eye health
A Chat with Anat
10/10/24 • 15 min
My guest for this special episode is Peter Holland, Chief Executive of the International Agency for the Prevention of Blindness (IAPB). We speak about the importance of World Sight Day, and discuss how different initiatives, such as the Love Your Eyes campaign, have helped put eye health on the global agenda in collaboration with members and partners.
We also highlight how clinicians can leverage their voices and influence to share knowledge, shape policies, and strengthen cross-sector collaborations, leading to the development of important resources for patients and clinicians to improve care. We recommend visiting the IAPB’s website, and the websites of the nAMD Barometer Program and Vision Academy for more information on World Sight Day, and resources to help you in your clinic.
If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to make sure you never miss an episode!
Speaker disclosures:
Professor Anat Loewenstein
Consultant: AbbVie, Bayer, Beyeonics, Syneos, Ripple, Iveric Bio, Johnson & Johnson, Ocuphire, Iqvia, Notal Vision, Novartis, and Roche.
Peter Holland
Employee: International Agency for the Prevention of Blindness.
Further information on topics discussed in this podcast:
Child eye health. The International Agency for the Prevention of Blindness. https://www.iapb.org/learn/vision-atlas/magnitude-and-projections/child-eye-health/. Accessed October 9, 2024.
October 2024 PP-PFM-OPHT-ALL-0042-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Optimal anti-VEGF therapy regimen
A Chat with Anat
09/25/23 • 28 min
In this episode, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney in Australia, and Dr Andrew Chang, Principal Retinal Specialist at the Sydney Retina Clinic and Day Surgery in Australia, share their thoughts on the optimal anti-VEGF therapy regimens to treat retinal vascular diseases, including nAMD and DME. They discuss how the best regimen should be effective in maintaining vision, proactive, individualized to the patient’s needs, and convenient for the patient.
Using prctical examples from their own clinics, Professor Mitchell and Dr Chang explore how to treat different patients with different levels of starting visual acuity, and how treatments for retinal vascular diseases have changed over time.
This podcast is produced in partnership with the Vision Academy, a group of internationally renowned retinal experts who collaborate to provide guidance to the retinal community on clinical challenges in ophthalmology and controversies in care.
The Vision Academy viewpoints providing guidance on clinically challenging situations, and other important resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before subscribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their thoughts on bilateral retinal disease and treatment, how to optimize treatment of patients with nAMD with macular neovascularization subtypes, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Further information on other studies mentioned in this episode:
ARIES study: Mitchell et al., Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen for Neovascular Age-Related Macular Degeneration. The ARIES Study: A Randomized Clinical Trial https://journals.lww.com/retinajournal/Fulltext/2021/09000/EFFICACY_AND_SAFETY_OF_INTRAVITREAL_AFLIBERCEPT.15.aspx
July 2023 MA-PFM-OPHT-ALL-1183-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Reducing the burden of bilateral injections
A Chat with Anat
07/21/23 • 20 min
We are delighted to announce that we are expanding A Chat with Anat! We will be partnering with the Vision Academy, a group of retinal experts who collaborate to provide guidance to the retinal community. I will be joined by internationally renowned Vision Academy experts to discuss practice-focused topics covering clinical challenges in ophthalmology and controversies in care.
In this episode of A Chat with Anat, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney, and Dr Alex Hunyor, Associate Professor of Ophthalmology at the University of Sydney, discuss pragmatic considerations to reduce the burden of bilateral anti-VEGF injections.
Professor Mitchell and Dr Hunyor explore how bilateral disease significantly impacts patient quality of life, and how bilateral treatment, especially if the eyes are being treated on different days, can lead to significant burden for patients, caregivers, and for their healthcare system.
Their conversation also covers how to explain to patients the need for, and risks of, bilateral injections, and how we, as ophthalmologists, can minimise any potential risks with the treatment procedure.
The Vision Academy viewpoint providing guidance on bilateral injections, and other important viewpoints and resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their experiences in navigating the importance of addressing anxiety and depression in our patients with nAMD, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
July 2023 MA-PFM-OPHT-ALL-1181-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Are we entering a new era for patients and clinicians?
A Chat with Anat
06/18/24 • 13 min
My guest for this special episode recorded live at the 15th Annual Congress on Controversies in Ophthalmology (COPHy) is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at University of Manchester, United Kingdom.
In this episode, Tariq and I discuss whether the introduction of next generation therapies for the clinical management of retinal diseases will open the door to a new era for patients and clinicians.
We also consider how learnings from the Barometer Global Survey surrounding the multiple challenges associated with management of retinal diseases can be implemented into clinical practice, and touch on how we can best support our patients to achieve extended treatment intervals.
If you want to know more about the Barometer Program’s Global Survey, or the Barometer’s efforts towards patient-focused care, visit our website: https://www.amdbarometer.org/. Also on the website are important materials resources to help you in your clinical practice (such as communication guides and educational materials) and to help your patients (such as information packs for patients to give to their employers).
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing how to choose the optimal anti-VEGF therapy regimen for patients with retinal vascular diseases, how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence, and how we as ophthalmologists can both understand and help patients with the burden of treatment.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources
This podcast was produced in association with the Vision Academy; viewpoints on clinically challenging situations, educational slide decks, video content and other materials, can be found at the Vision Academy, https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy: Allergan, Annexon, Bayer, Beyeonics, Biogen, ForSight Labs, Iqvia, Iveric Bio, Johnson & Johnson, MJHEvents, Nanoretina, Notal Vision, Novartis, Ocuphire Pharma, Ocuterra, Ophtimedrx, Ripple Therapeutics, Roche, Syneos, WebMD, and Xbrane.
Professor Tariq Aslam
Gra
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Impact of residual fluid on treatment outcomes in nAMD
A Chat with Anat
08/08/24 • 26 min
In this episode, my guests Vision Academy and Barometer Program member Professor Jean-François Korobelnik, Professor and Head of the Ophthalmology Department at the University Hospital of Bordeaux in France, and Vision Academy member Professor Robyn Guymer, Deputy Director at the Centre for Eye Research and Professor of Ophthalmic at the University of Melbourne in Australia, discuss considerations for devising flexible and individualized treatment regimens for patients with nAMD with residual fluid.
Using examples from their own clinical experience, Professors Korobelnik and Guymer explore the nuanced relationship between efficacy of anti-VEGF treatment and location and presence (or absence) of fluid in patients with nAMD.
The Vision Academy Viewpoint providing recommendations for the assessment and monitoring of fluid status can be found on the website, along with other viewpoints and resources. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.
Speaker disclosures:
Professor Jean-François Korobelnik
Consultancy: Abbvie, Allergan, Apellis, Bayer, Carl Zeiss Meditec, Janssen, NanoRetina, Roche, and Théa.
Professor Robyn Guymer
Advisory boards and/or Consultancy: Apellis, Bayer, Belite Bio, Boehringer Ingelheim Pharmaceuticals, Character Bioscience, Genentech, Novartis, Ocular Therapeutix, and Roche.
Further information on residual fluid:
Arnold J.J, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/
Lek JJ., et al. Interpretation of subretinal fluid using OCT in intermediate age-related macular degeneration. Ophthalmol Retina. 2018. https://www.sciencedirect.com/science/article/abs/pii/S2468653017307315?via%3Dihub
Hahn P, Eliott D, eds. 2021 Global Trends in Retina Survey. 2021. https://www.asrs.org/content/documents/20
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
08/19/22 • 17 min
My guest for this episode is Professor Paul Mitchell, Emeritus Professor of Ophthalmology at the University of Sydney, Consultant Ophthalmologist at the Western Sydney Local Health District, and Principal of Sydney West Retina Pty Ltd in Australia.
As treatment for neovascular age-related macular degeneration (nAMD) has evolved through the 21st century, so have the expectations of our patients. Paul joins me to chat about how developments in treatment modalities and regimens led to the evolution of patient expectations following diagnosis of nAMD, and what we can expect for our patients in the future.
If you enjoyed this episode, try some of our past episodes to hear other retinal experts delve into ways in which we can engage and empower our patients, how to further motivate our patients to be adherent, and how clinic organization can be used to improve adherence and persistence.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/
Further information on studies mentioned in this episode:
Blue Mountains Eye study (https://doi.org/10.1016/S0161-6420(95)30846-9)
MARINA study (https://doi.org/10.1056/NEJMoa054481)
ANCHOR study (https://doi.org/10.1016/j.ophtha.2008.10.018)
LUCAS study (https://doi.org/10.1016/j.ophtha.2014.07.041)
ALTAIR study (https://doi.org/10.1007/s12325-020-01236-x)
ARIES study (https://doi.org/10.1097/IAE.0000000000003128)
HOME study (https://doi.org/10.1016/j.cct.2014.02.003)
Algorithm for suspending anti-VEGF treatment in cases of futility (https://doi.org/10.1097/IAE.0000000000002713)
June 2024 MA-PFM-OPHT-ALL-0938-1
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
Professor Paul Mitchell
Consultancy: Allergan, Bayer, and Novartis
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Exploring the research gap of patient perspectives
A Chat with Anat
11/15/22 • 17 min
My guest for this episode is Professor Richard Gale, Professor of Ophthalmology at Hull York Medical School, University of York, UK, and Honorary Consultant Medical Ophthalmologist at the National Health Service’s York Teaching Hospital.
In this episode, Richard and I will chat about how patients’ emotions, experiences, and perceptions related to anti-vascular endothelial growth factor (anti-VEGF) treatment can influence their treatment adherence and persistence. Despite this, the patient’s perspective is often not considered during the clinical management of neovascular age-related macular degeneration. To tackle this issue, Richard gives us some of his top tips to try in our busy clinics.
We discuss a systematic literature review article recently published in Acta Ophthalmologica, which was authored by a group of international experts including Richard and myself. Find out more here: https://doi.org/10.1111/aos.15201
If you enjoyed this episode, go back and listen to our first episode with Richard, where we chat about how to further motivate our patients to be adherent, or try some of the past episodes to hear other retinal experts delve into ways to engage and empower our patients, and explore a history of patient expectations in nAMD through the 21st century.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/
Further information on other studies mentioned in this episode:
ANCHOR study: https://doi.org/10.1016/j.ophtha.2008.10.018
MARINA study: https://doi.org/10.1016/j.ophtha.2006.10.045
Prevalence and risk factors for depressive symptoms in patients with nAMD; Australian study: https://doi.org/10.1111/aos.14635
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences.
This is not intended for UK audiences.
Speaker disclosures:
Professor Anat Loewenstein
Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane
Professor Richard Gale:
Consultancy, Research
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Characterization of macular neovascularization subtypes in nAMD to optimize treatment outcomes
A Chat with Anat
05/14/24 • 20 min
My guest for this episode is Professor Nicole Eter, Professor of Ophthalmology and Chair of the Department of Ophthalmology at the University of Münster, Germany. In this episode, Nicole and I chat about the different macular neovascularization (MNV) subtypes, discussing the diagnostic tools used to classify MNV subtypes, their defining characteristics and variants, and the impact of these on our patients.
Our conversation highlights why it’s important to tailor treatment to MNV subtype for our patients to have the best outcomes, and the significance of discussing lesions, prognoses and treatments with patients and their caregivers. Important resources, such as the Vision Academy Viewpoint on MNV subtypes and treatment algorithms and educational slide decks, can be found on the https://www.visionacademy.org/. Or can be downloaded directly from here; view point and slide deck. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here at: https://www.amdbarometer.org/resources
Speaker disclosures:
Professor Anat Loewenstein
Consultancy: Allergan, Annexon, Bayer, Beyeonics, Biogen, ForSight Labs, Iqvia, Iveric Bio, Johnson & Johnson, MJHEvents, Nanoretina, Notal Vision, Novartis, Ocuphire Pharma, Ocuterra, Ophtimedrx, Ripple Therapeutics, Roche, Syneos, WebMD, and Xbrane.
Professor Nicole Eter
Consultancy: Alcon, Allergan, Apellis, Bayer, Novartis, and Roche; Payments/honoraria: Allergan, Apellis, Bayer, Novartis, and Roche; Research grants: Bayer and Novartis; Support for meetings/travel: Roche.
Further information on other studies mentioned in this episode:
Mathis T, et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye. 2022. https://www.nature.com/articles/s41433-022-02231-y
Spaide RF, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020.
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
01/08/25 • 17 min
My guest for this special episode is Dr. John Kitchens, Vitreoretinal Surgeon with Retina Associates of Kentucky in the USA. In this episode, John and I explore the importance of holistic patient care. We also highlight the latest advances in home monitoring technologies in retinal disease, and how artificial intelligence (AI) can be used to aid in disease monitoring and optimization of clinic organization.
To learn more about the current status of AI in screening, diagnosing and managing retinal diseases, read the Vision Academy Viewpoint, and the Vision Academy retinal expert consensuses by clicking here or here. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!
Speaker disclosures:
Professor Anat Loewenstein- Consultant: Consultant for 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos.
Dr. John Kitchens - Consultant: Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker: Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron.
Further information on topics discussed in this podcast:
Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417–1436.
The Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, et al. Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4. JAMA Ophthalmol. 2013;131:843–850.
Anguita R, Ferro Desideri L, Loewenstein A, et al. The digital age in retinal practice. Int J Retina Vitreous. 2024 Sep 26;10:67. doi: 10.1186/s40942-024-00580-2.
January 2025 PP-PF-OPHT-ALL-0199-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Show more best episodes
Show more best episodes
FAQ
How many episodes does A Chat with Anat have?
A Chat with Anat currently has 17 episodes available.
What topics does A Chat with Anat cover?
The podcast is about Life Sciences, Podcasts, Science and Ophthalmology.
What is the most popular episode on A Chat with Anat?
The episode title 'Pachychoroid: Current concepts on clinical features and pathogenesis' is the most popular.
What is the average episode length on A Chat with Anat?
The average episode length on A Chat with Anat is 19 minutes.
How often are episodes of A Chat with Anat released?
Episodes of A Chat with Anat are typically released every 63 days, 5 hours.
When was the first episode of A Chat with Anat?
The first episode of A Chat with Anat was released on Oct 1, 2021.
Show more FAQ
Show more FAQ